Press release
Primary Axillary Hyperhidrosis Pipeline 2025: Key Clinical Developments by 5+ Global Leaders - DelveInsight | Featuring Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff GmbH & Co. KG
Primary Axillary Hyperhidrosis Pipeline 2025
As Primary Axillary Hyperhidrosis becomes increasingly prevalent worldwide and is linked to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising need for safer and more effective therapies. According to DelveInsight, the pipeline for Primary Axillary Hyperhidrosis includes 5+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates. These candidates are at various stages of clinical and preclinical development, reflecting significant innovation and dedication to tackling this public health concern.
DelveInsight's "Primary Axillary Hyperhidrosis Pipeline Insight 2025" report offers a comprehensive evaluation of the current R&D landscape. It highlights clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as a valuable resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving Primary Axillary Hyperhidrosis therapeutics market and the innovations shaping its future.
Explore the Cutting-Edge Landscape of Primary Axillary Hyperhidrosis Drug Development [https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:
*
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).
*
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.
*
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).
*
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.
*
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.
*
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER Trademark program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.
*
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.
*
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT Trademark study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.
Key Takeaways from the Primary Axillary Hyperhidrosis Pipeline Report
*
DelveInsight's Primary Axillary Hyperhidrosis pipeline report highlights a dynamic landscape with 5+ active companies developing 5+ therapeutic candidates for the treatment of Primary Axillary Hyperhidrosis.
*
In June 2024, the U.S. Food and Drug Administration (FDA) approved Sofdra Trademark (sofpironium bromide) topical gel, 12.45% for managing primary axillary hyperhidrosis, a condition marked by excessive underarm sweating. This approval represents the first new chemical entity in the U.S. specifically indicated for this disorder.
*
Leading companies in the Primary Axillary Hyperhidrosis space, including Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff GmbH & Co. KG Arzneimittel, and others, are actively developing new treatments to enhance the therapeutic landscape. Promising pipeline candidates at various stages of development include Sofpironium Bromide, DMT-410, and additional therapies.
Primary Axillary Hyperhidrosis Overview:
Primary hyperhidrosis is a rare disorder characterized by excessive sweating in localized areas, including the palms, soles, groin, or under the breasts. A common form, Primary Axillary Hyperhidrosis, specifically involves overactive underarm sweating. Although the precise cause is not fully understood, it is thought to arise from increased cholinergic sympathetic nerve activity that overstimulates the sweat glands in the underarms. The condition affects both men and women equally and usually emerges during childhood or adolescence.
Download the Primary Axillary Hyperhidrosis sample report to know in detail about the Primary Axillary Hyperhidrosis treatment market [https://www.delveinsight.com/sample-request/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Primary Axillary Hyperhidrosis Pipeline Analysis
The Primary Axillary Hyperhidrosis pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Primary Axillary Hyperhidrosis Market.
*
Categorizes Primary Axillary Hyperhidrosis therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Primary Axillary Hyperhidrosis drugs under development based on:
*
Stage of development
*
Primary Axillary Hyperhidrosis Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Primary Axillary Hyperhidrosis Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Primary Axillary Hyperhidrosis Licensing agreements
*
Funding and investment activities supporting future Primary Axillary Hyperhidrosis market advancement.
Unlock key insights into emerging Primary Axillary Hyperhidrosis therapies and market strategies here: https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Primary Axillary Hyperhidrosis Emerging Drugs
Sofpironium Bromide - Brickell Biotech Inc.
Brickell Biotech's leading investigational drug, Sofpironium Bromide, is a topically applied small-molecule therapy developed for Primary Axillary Hyperhidrosis. It acts as a retro-metabolically engineered anticholinergic, selectively targeting M3 acetylcholine receptors, with the potential to decrease sweat gland activity.
DMT-410 - Dermata Therapeutics LLC
Dermata Therapeutics is advancing DMT-410, a combination therapy that integrates DMT-310 with botulinum toxin, for the treatment of axillary hyperhidrosis. This therapeutic approach has shown promising results in Phase I clinical trials.
Primary Axillary Hyperhidrosis Pipeline Therapeutic Assessment
Primary Axillary Hyperhidrosis Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Primary Axillary Hyperhidrosis By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Primary Axillary Hyperhidrosis Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Primary Axillary Hyperhidrosis Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Primary Axillary Hyperhidrosis therapies and key Primary Axillary Hyperhidrosis companies: https://www.delveinsight.com/sample-request/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Primary Axillary Hyperhidrosis Current Treatment Patterns
4. Primary Axillary Hyperhidrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Axillary Hyperhidrosis Late-Stage Products (Phase-III)
7. Primary Axillary Hyperhidrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Axillary Hyperhidrosis Discontinued Products
13. Primary Axillary Hyperhidrosis Product Profiles
14. Primary Axillary Hyperhidrosis Key Companies
15. Primary Axillary Hyperhidrosis Key Products
16. Dormant and Discontinued Products
17. Primary Axillary Hyperhidrosis Unmet Needs
18. Primary Axillary Hyperhidrosis Future Perspectives
19. Primary Axillary Hyperhidrosis Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Primary Axillary Hyperhidrosis pipeline reports offerings [https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-axillary-hyperhidrosis-pipeline-2025-key-clinical-developments-by-5-global-leaders-delveinsight-featuring-brickell-biotech-inc-dermata-therapeutics-llc-dr-august-wolff-gmbh-co-kg]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Axillary Hyperhidrosis Pipeline 2025: Key Clinical Developments by 5+ Global Leaders - DelveInsight | Featuring Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff GmbH & Co. KG here
News-ID: 4206177 • Views: …
More Releases from ABNewswire
Lone Wolf Siding Emerges as the Best Siding Company in New Orleans Offering Prem …
Lone Wolf Siding is the best siding company in New Orleans, Louisiana.
Image: https://www.abnewswire.com/upload/2025/09/3522ab792132a4d3ddba57316984a0de.jpg
Lone Wolf Siding, a trusted siding contractor in New Orleans, proudly announces its expanded offerings designed to protect and enhance homes across Louisiana. With a strong foundation in expert siding installation and repair, the company now provides homeowners with a full suite of exterior solutions, including patios and pergolas, all backed by exceptional craftsmanship and a 100% satisfaction…
Buerger's Disease Pipeline 2025: Pioneering Clinical Developments by 3+ Global L …
DelveInsight's, "Buerger's Disease - Pipeline Insight, 2025," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Buerger's Disease increasingly affects populations worldwide and is linked…
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical Progress by 8+ Glob …
DelveInsight's, "Mucopolysaccharidosis III - Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Mucopolysaccharidosis III pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Mucopolysaccharidosis III (MPS III) is emerging as a significant global…
Ovarian Cancer Clinical Trials, Companies, Therapeutic Assessment, Emerging Ther …
Ovarian Cancer companies are Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others.
Ovarian Cancer Pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analyzes DelveInsight.
Ovarian Cancer Overview:
Ovarian cancer is the deadliest gynecological cancer and the…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
